Latest Content

I share how the holidays feel different after loss and how grief, love and gratitude can coexist as I navigate this season with gentleness and care.

Dr. Charles M. Rudin highlights T cell engagers, antibody-drug conjugates and emerging strategies showing early benefits for small cell lung cancer.

The phase 2 SANRECO study has recently completed enrollment and will evaluate divesiran, a potential therapy for patients with polycythemia vera.

Voranigo was safe and well tolerated in patients with grade 3 or 4 IDH-mutant gliomas, a type of brain cancer.

Sac-TMT plus Keytruda improved time without cancer growth in people with advanced lung cancer whose tumors show programmed death ligand 1.

Imbruvica plus R-MPV led to high response rates and was tolerable for patients with newly diagnosed primary central nervous system lymphoma.

Dr. Pamela L. Kunz sat down for an interview with CURE to discuss resources and ongoing initiatives that may help patients with this disease.

Eflornithine plus Gleostine was associated with superior overall survival and progression-free survival in grade 3 IDH-mutated astrocytoma.

Intraventricular B7-H3 CAR T-cell therapy was well tolerated up to 1 x 10⁷ cells per infusion and showed early signs of activity in recurrent glioblastoma.

Early data from the SJ901 study show Gomekli generates responses with manageable side effects in children and young adults with low grade glioma.

Early data indicate Voranigo is rapidly being used in newly diagnosed and previously treated patients with IDH-mutant glioma, highlighting ongoing treatment needs.

Researchers identified a potential unmet need for an effective early treatment with minimal toxicity for patients with slow-growing IDH-mutant gliomas.

Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive cisplatin after surgery.